What information is given on adverse drug reactions from new drugs?;Hvilken informasjon gis orn bivirkninger av nye legemidler?

Tidsskrift for den Norske Laegeforening

Volumn 123, Issue 17, 2003, Pages 2414-2417

  Eldholm, Rannveig Sakshaug ^a   Bergheim, Terese Stavenjord ^a   Slørdal, Lars ^a   Spigset, Olav ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID CALCIUM; AMITRIPTYLINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BENZODIAZEPINE DERIVATIVE; BISPHOSPHONIC ACID DERIVATIVE; CAPTOPRIL; CHLORPROMAZINE; DEXCHLORPHENIRAMINE; DIAZEPAM; DIGITOXIN; DIGITRIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETIDRONIC ACID; FLUVOXAMINE; FLUVOXAMINE MALEATE; FUROSEMIDE; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOSARTAN; LOSARTAN POTASSIUM; MEVINOLIN; MORPHINE; OMEPRAZOLE; PENICILLIN V; POLARAMIN; PREDNISOLONE; PROTON PUMP INHIBITOR; SEROTONIN UPTAKE INHIBITOR; WARFARIN; WEIFAPENIN; ZOPICLONE; DRUG;

ARTICLE; DRUG APPROVAL; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG INFORMATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; HUMAN; NORWAY; PHYSICIAN; POSTMARKETING SURVEILLANCE; PRESCRIPTION; PUBLICATION; SYMPTOM; DRUG INTERACTION;

ADVERSE DRUG REACTION REPORTING SYSTEMS; CATALOGS, DRUG; DRUG APPROVAL; DRUG INFORMATION SERVICES; DRUG INTERACTIONS; HUMANS; NORWAY; PHARMACEUTICAL PREPARATIONS;

EID: 0642345020     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Brewer T, Colditz G. Postmarketing surveillance and adverse drug reactions: current perspectives and future needs. JAMA 1999; 281: 824-9.
2. Lasser KE, Allen PD, Woolhandler SJ, Himmlestein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002; 287: 2215-20.
3. Laurence DR, Bennett PN, Brown MJ. Clinical pharmacology. Edinburgh: Churchill Livingstone, 1997: 124.
4. Kalant H, Roschlau WHE. Principles of medical pharmacology. New York: Oxford University Press, 1998: 791-8.
5. Bakke OM, Wardell WM, Lasagna L. Drug discontinuation in the United Kingdom and the United States, 1964 to 1986: issues of safety. Clin Pharmacol Ther 1984; 35: 559-67.
6. Bakke OM, Manocchia M, de Abajo F, Kaitin KI, Lasagna L. Drug safety discontinuations in the United Kingdom, the United States and Spain from 1974 through 1993: a regulatory perspective. Clin Pharmacol Ther 1995; 58: 108-17.
7. Jefferys DB, Leakley DL, Lewis JA, Payne S, Rawlins MD. New active substances authorized in the United Kingdom between 1972 and 1994. Br J Clin Pharmacol 1998; 45: 151-6.
8. Spriet-Pourra C, Auriche M. Drug withdrawal from the market for safety in the European countries: contributing reasons and implications. I: Fracchia GN, red. European medicines research. Amsterdam: IOS Press, 1994:267-75.
9. Kaufman DW, Shapiro S. Epidemiological assessment of drug-induced disease. Lancet 2000; 356: 1339-43.
10. Felleskatalog over farmasøytiske spesialpreparater markedsføert i Norge 2001. 43. utg. Oslo: Felleskatalogen AS, 2001.
11. FASS. Läkemedel i Sverige 2001. Stockholm: LINFO Läkemedelsinformation AB, 2001.
12. Critical terms list, December 2001. Uppsala: World Health Organisation Collaborating Centre for International Drug Monitoring, 2001.
13. Gruchalla RS. Clinical assessment of drug-induced disease. Lancet 2000; 356: 1505-7.
14. http://www.legemiddelverket.no/bivirk/prepfok/cox-2.htm (3.6.2002).
15. Myhr K. Kan vi stole på preparatomtaler? Tidsskr Nor Lægeforen 2002; 122: 2644-6.
16. Strom BL, red. Pharmacoepidemiology. 3. utg. Chichester: John Wiley & Sons, 2000.